Cellebrite DI Ltd. (CLBT)
(Delayed Data from NSDQ)
$11.98 USD
-0.26 (-2.12%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $11.97 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLBT 11.98 -0.26(-2.12%)
Will CLBT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CLBT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLBT
Cellebrite DI Ltd. (CLBT) Q1 Earnings and Revenues Surpass Estimates
Arbe Robotics Ltd. (ARBE) Reports Q1 Loss, Lags Revenue Estimates
CLBT: What are Zacks experts saying now?
Zacks Private Portfolio Services
FUTU vs. CLBT: Which Stock Should Value Investors Buy Now?
Is Cellebrite DI Ltd. (CLBT) Stock Outpacing Its Business Services Peers This Year?
Are Business Services Stocks Lagging Cellebrite DI Ltd. (CLBT) This Year?
Other News for CLBT
Cellebrite DI’s Strategic Growth Plan and Positive Market Positioning Garner Buy Rating
Cellebrite management to meet virtually with Lake Street
Cellebrite DI (CLBT) Gets a Buy from Craig-Hallum
Analysts Offer Insights on Technology Companies: Cellebrite DI (CLBT), International Money Express (IMXI) and NICE (NICE)
Cellebrite management to meet with Craig-Hallum